卡培他滨联合肝动脉注射表柔比星和顺铂治疗不可切除胆管癌：一项II期研究。
Capecitabine plus hepatic intra-arterial epirubicin and cisplatin in unresectable biliary cancer: a phase II study.
作者信息
Mambrini Andrea, Guglielmi Alfredo, Pacetti Paola, Iacono Calogero, Torri Tito, Auci Alessio, Nicoli Nicola, Orlandi Massimo, Guadagni Stefano, Fiorentini Giammaria, Cantore Maurizio
机构信息
Department of Oncology and 3Radiology, Carrara City Hospital, Carrara, Italy.
出版信息
Anticancer Res. 2007 Jul-Aug;27(4C):3009-13.
UNLABELLED
The aim of the present study was to evaluate the activity of hepatic intra-arterial infusion of epirubicin and cisplatin combined with oral capecitabine, in patients with unresectable biliary carcinomas.
PATIENTS AND METHODS
Twenty patients were treated by bolus infusion of epirubicin 50 mg/m2 and cisplatin 60 mg/m2 in the hepatic artery on day 1, combined with oral capecitabine 1000 mg/m2 bid, from day 2 to day 15.
RESULTS
Partial responses (PR) were observed in 6 patients (31.5%), stable disease (SD) in 9 (47.5%) and progression (PD) in 4 (21%). The median progression-free and overall survival periods were 11.6 and 18.0 months, respectively, and 1-year survival was 74%. One patient died after the first cycle because of G4 diarrhea. The other patients had good tolerance, with minimal hematological toxicity and only 1 G3 vomiting.
CONCLUSION
This combined intra-arterial and oral approach to patients with biliary carcinomas was found to be active and safe and seems to produce an encouraging survival response.
未标注
本研究的目的是评估肝动脉内灌注表柔比星和顺铂联合口服卡培他滨对不可切除胆管癌患者的疗效。
患者与方法
20例患者于第1天在肝动脉内推注表柔比星50mg/m²和顺铂60mg/m²，并于第2天至第15天联合口服卡培他滨1000mg/m²，每日2次。
结果
6例患者（31.5%）出现部分缓解（PR），9例（47.5%）病情稳定（SD），4例（21%）病情进展（PD）。无进展生存期和总生存期的中位数分别为11.6个月和18.0个月，1年生存率为74%。1例患者在第一个周期后因4级腹泻死亡。其他患者耐受性良好，血液学毒性极小，仅1例出现3级呕吐。
结论
这种肝动脉内和口服联合治疗胆管癌患者的方法被发现是有效且安全的，似乎能产生令人鼓舞的生存反应。
Zotero 插件